Literature DB >> 10987146

Mutation analysis of Korean patients with citrullinemia.

K M Hong1, C H Shin, Y B Choi, W K Song, S D Lee, K I Rhee, P Jang, G S Pak, J K Kim, M K Paik, S H Hahn.   

Abstract

Citrullinemia is an autosomal recessive disease due to the mutations in the argininosuccinate synthetase (ASS) gene. Mutation analysis was performed on three Korean patients with citrullinemia. All of the three patients had the splicing mutation previously reported as IVS6-2A>G mutation. Two had Gly324Ser mutation and the other patient had a 67-bp insertion mutation in exon 15. The IVS6-2A>G mutation was reported to be found frequently in Japanese patients with citrullinemia, but Caucasian patients showed the extreme mutational heterogeneity. Although a limited number of Korean patients were studied, the IVS6-2A>G mutation appears to be one of the most frequent mutant alleles in Korean patients with citrullinemia. The Gly324Ser mutation identified in two patients also suggests the possible high frequency of this mutation in Korean patients as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987146

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  3 in total

1.  Predisposition of genetic disease by modestly decreased expression of GCH1 mutant allele.

Authors:  Yo Sik Kim; Yong Bock Choi; Jeong Hwa Lee; Sei Hoon Yang; Ji Hyun Cho; Chang Ho Shin; Sang Do Lee; Moon Kee Paik; Kyeong Man Hong
Journal:  Exp Mol Med       Date:  2008-06-30       Impact factor: 8.718

Review 2.  Contrasting features of urea cycle disorders in human patients and knockout mouse models.

Authors:  Joshua L Deignan; Stephen D Cederbaum; Wayne W Grody
Journal:  Mol Genet Metab       Date:  2007-10-22       Impact factor: 4.797

Review 3.  Citrullinemia type I is associated with a novel splicing variant, c.773 + 4A > C, in ASS1: a case report and literature review.

Authors:  Yiming Lin; Hongzhi Gao; Bin Lu; Shuang Zhou; Tianwen Zheng; Weihua Lin; Lin Zhu; Mengyi Jiang; Qingliu Fu
Journal:  BMC Med Genet       Date:  2019-06-17       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.